肺癌靶向治疗研究进展

晚期非小细胞肺癌EGFR TKI获得性耐药的热点研究及进展 主要内容 EGFR TKI作用机制 耐药机制新药临床研究前景展望 EGFR ERBB3 AKT EGFR信号传导的分子机制J EGFR GefitinibErlotinib EGFR TKI作用机制 主要内容 EGFR TKI作用机制 耐药机制新药研究前景展望 EGFR TKI耐药机制 49 5 3 2 11 23 2 3 T790 EGFR ERBB3 AKT T790 GefitinibErlotinib T790M介导EGFR TKI耐药机制 EGFR TKI耐药热点研究梳理 EGFR tki耐药 MET抑制剂 AfatinibDacomitinib C01686 Rociletinib RociletinibinEGFR MutatedNon Small CellLungCancer NCT01526928 NEnglJMed2015 372 1700 1709April30 2015DOI 10 1056 NEJMoa1413654 BestResponsetoRociletinib Eachbarrepresentsanindividualpatient andtheamplitudeanddirectionofthebarrepresentthepercentchangeintumorburdenduringtreatmentascomparedwithbaseline Tumorburdenwasmeasuredasthesumofthelongestdiametersofthetargetlesions accordingtotheResponseEvaluationCriteriainSolidTumors version1 1 Thedashedlineat20 representstheboundaryfordeterminationofprogressivedisease andthedashedlineat 30 representstheboundaryfordeterminationofpartialresponse FBdenotesfreebase andHBrhydrogenbromidesalt RociletinibinEGFR MutatedNon Small CellLungCancer NCT01526928 NEnglJMed 2015Apr30 372 18 1689 99 doi 10 1056 NEJMoa1411817 AZD9291inEGFRInhibitor ResistantNon Small CellLungCancer NCT01802632 AZD9291 AZD9291inEGFRInhibitor ResistantNon Small CellLungCancer NCT01802632 AZD9291inEGFRInhibitor ResistantNon Small CellLungCancer NCT01802632 AZD9291inEGFRInhibitor ResistantNon Small CellLungCancer NCT01802632 前景展望 3代TKI药物应用于耐药的晚期NSCLC患者前景良好 期临床试验已完成 期待 期临床试验